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See Article, pages 462–469Non-alcoholic fatty liver disease (NAFLD) affects 75–100 million
US adults and is increasingly recognized worldwide. The interme-
diate stage of non-alcoholic steatohepatitis (NASH) may progress
to advanced hepatic ﬁbrosis and/or cirrhosis. Thus, it is imperative
for the medical community to identify and modify potential risks
for NAFLD disease acquisition and progression. Recently,
increased sugar intake, in particular fructose, has experienced a
resurgence of interest and controversy. The rise in dietary fructose
consumption, primarily from sugar sweetened beverages (SSB), is
at the forefront of interest and controversy from a public health
perspective. Fructose, likened to addictive drugs and reviled as a
scourge of the modern diet [1] has been implicated as a unique
modiﬁable dietary risk factor for the rise of obesity [2], diabetes
[4], cardiovascular disease [2], and recently NAFLD [3,4].
SSB contribute to obesity through their ‘‘add-on’’ caloric load.
Several randomized trials of SSB show that sucrose, 50% of which
is fructose, or fructose alone increases body weight, visceral
adipose tissue, muscle fat, and liver fat. Metabolized rapidly
and primarily through ﬁrst-pass metabolism in the liver via fruc-
tokinase, fructose metabolism increases de novo lipogenesis,
serum triglycerides, and uric acid thereby inducing mitochondrial
oxidant stress and a transient depletion of intracellular phos-
phate and ATP. By virtue of its metabolic consequences, the
increased intake of fructose and/or sucrose, has been proposed
to be hazardous to the health of some people and deemed a risk
factor for NAFLD acquisition and progression.
The inherent challenges of studying excess sugar consump-
tion and in particular fructose as a single dietary nutrient in
humans include inaccurate assessment of carbohydrate con-
sumption, inability to isolate fructose from other dietary carbo-
hydrates and the current lack of well-designed clinical studies.
The complexities and controversies over study designs pertains
to the relevance of the doses of fructose administered, whether
total caloric intake is isocaloric or hypercaloric, relatively small
sample sizes, lack of long-term follow-up, lack of accurate mea-
sures for determining the presence or absence of NAFLD, as wellJournal of Hepatology 20
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patients at risk (i.e. healthy controls without risks for metabolic
disease versus those with insulin resistance).
In the current issues of the Journal of Hepatology, Ma et al.
examine the cross-sectional association between habitual SSB,
diet soda intake, liver fat measured by multidetector computed
tomography (MDCT) and alanine aminotransferase (ALT) levels
in the Framingham Heart Study cohorts. The analysis included
2634 participants with interpretable MDCT scans, food frequency
questionnaire (FFQ) data, low levels of alcohol consumption and
available ALT measures. Participants were categorized as either
non-consumers or consumers (three categories: 1 serving/month
to <1 serving/week, 1 serving/week to <1 serving/day, and
P1 serving/day) of SSB or diet soda. After adjustment for con-
founding, the odds of NAFLD were 1, 1.16 (0.88, 1.54), 1.32 (0.93,
1.86), and 1.61 (1.04, 2.49) across SSB consumption categories
(p = 0.04). SSB consumption was also positively associated with
ALT levels (p = 0.007). The effects of SSB in overweight and obese
subjects were more pronounced than those with normal BMI.
The latter ﬁndingswere not observedwith diet soda consumption.
At ﬁrst blush, it is encouraging to note that the prevalence of
NAFLD in the study cohort is lower (17%) than current prevalence
estimates for NAFLD in the general population. The relatively
lower prevalence of NAFLD in this study could reduce the ability
to detect signiﬁcant differences among SSB categories and results
in a non-differential misclassiﬁcation effort of MDCT; however, a
signiﬁcant increasing trend of NAFLD across SSB consumption
categories was still noted. Interestingly, daily SSB consumers
had a 56% higher risk of NAFLD compared to non consumers.
SSB consumption was associated with higher liver fat content
and increased ALT among overweight and obese but not in nor-
mal weight persons. After controlling for potential confounders,
diet soda intake was not associated with NAFLD or changes in
ALT. Using strict ALT cut-off values of 19 U/L for women and
30 U/L for men [5], daily SSB consumption was independently
associated with a 36% increased risk of elevated ALT levels
(OR = 1.36, 95% CI 1.09, 1.70). The association of SSB with
increased ALT in this study as well as with increased fasting
plasma insulin levels and HOMA-IR [6] lend weight to the con-
cern that SSB also increases the risk of NASH.15 vol. 63 j 306–308
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The acquisition and progression of NAFLD have been previ-
ously been reported to be associated with SSB intake. Patients
with NAFLD consume more simple carbohydrates than the gen-
eral population [7] and consumption of SSB is a common risk fac-
tor for NAFLD in the absence of other classic risk factors [8].
Patients with biopsy-proven NAFLD compared to matched con-
trols without NAFLD consume 2–3 fold more SSB and this was
associated with increased expression of fructose-metabolizing
enzymes in the liver [4]. The associated alterations in hepatic
energy homeostasis [9] and/or the fermentation of fructose
endogenously to ethanol by the gut-microbiome [1] may serve
as an alternative mechanism for the variable risk of fructose-re-
lated liver injury in susceptible individuals [10]. In this regard,
SSB intake has previously been associated with increased NASH
and hepatic ﬁbrosis in patients with NAFLD [3].
Several investigators have argued that the role of excess carbo-
hydrates in general, as opposed to fructose per se, is the cause of
metabolic syndrome and NAFLD; however, this remains controver-
sial [11]. A feeding study of either 25% calories from glucose- or
fructose-sweetened beverages, demonstrated that fructose- but
not glucose-sweetened beverages increases visceral adiposity,
serum lipids, and decreases insulin sensitivity in overweight and
obese subjects [12]. Fructose, but not glucose, led to signiﬁcant
increases of 24 hour uric acid proﬁles (p <0.0001) and retinol
binding protein-4 concentrations (p = 0.012), as well as plasma
GGT activity (p = 0.04) [12]. Because glucose and fructose are
often consumed together in the form of sucrose, the same group
of investigators performed a subsequent study comparing fruc-
tose as 25% calories to an isocaloric glucose-containing diet.
Unlike glucose, fructose increased post-prandial triglycerides,
low-density lipoprotein cholesterol, and apolipoprotein B levels
suggesting that fructose increases de novo lipogenesis and hepatic
steatosis compared to glucose [13]. However, another study
reported that overweight men fed a high fructose or a high-glu-
cose isocaloric diet for two weeks did not develop any signiﬁcant
changes in hepatic concentration of TAGs or serum levels of liver
enzymes. However, a high fructose and high glucose hypercaloric
diets produced signiﬁcant increases in TAGs and serum liver
enzymes without any signiﬁcant difference between the two
groups indicating an energy-mediated, rather than a speciﬁc
macronutrient-mediated, effect [14]. Although very few studies
of the long-term effects of fructose consumption exist, one study
compared the effects of sucrose-sweetened soft drinks with those
of isocaloric milk and a diet soft drink which demonstrated
increased ectopic fat in the liver and muscle tissue and increased
serum lipids compared to milk, diet soft drinks and water [15].
As suggested by the study of Ma et al., overweight and obese
persons may be at increased risk of fructose-related liver injury
than healthy adults. In an exploratory, randomized, single-
blinded, intervention trial, neither fructose nor glucose
(150 g/day for four weeks) increased hepatic triglyceride concen-
trations in healthy adults, although both increased serum triglyc-
erides [16]. Likewise, children fed fructose as 33% of calories for
one day had increase serum triglycerides; however, the effect
was greater in children with NAFLD compared with children
without NAFLD. When lean healthy children of diabetic parents
were fed a high fructose diet, they were also more likely to
increase liver fat than controls suggesting a genetic predisposi-
tion to fructose-related metabolic and hepatic consequences.
Whether genetic (i.e. polymorphisms in PNPLA3, lysophospha-
tidic acid acyltransferase (LPAAP, AGPAT2), or fructokinase [17])Journal of Hepatology 201or epigenetic risk factors [18,19] are associated with fructose-
related liver injury remains unknown.
While the results reported by Ma et al. provide further support
for dietary recommendations to limit and/or avoid SSB in patients
with pre-existing metabolic syndrome, obesity and/or NAFLD, the
cross-sectional and observational design limits the ability to infer
temporality and/or causality between increased sugar intake and
NAFLD. Part of the inability of existing studies to clearly deﬁne the
health implications of fructose may be explained by the fact that
intake of sucrose, fructose, fruit juices, and/or sweetened bever-
ages was not recorded separately, thus precluding an accurate
assessment of total fructose intake from various sources isolated
from that of glucose. Controversy is fueled by extreme designs
of animal studies bearing little resemblance in the amount or pat-
tern to human fructose intake, emphasis on statistical rather than
clinical signiﬁcance, small sample sizes, confounding from excess
energy intake, and the lack of long-term randomized prospective
studies which isolate fructose as the primary predictor of clinical
outcomes. To understand better the role of fructose in NAFLD,
there is a need for larger, longer, high-quality prospective trials
of the effect of ‘‘real-world’’ intake patterns, as well as dose
thresholds for the effect of fructose on histopathological changes
associated with NAFLD. There is currently no evidence to suggest
the moderate intake of natural fructose as would be consumed
with fruits, vegetable or honey is unsafe.
In the heat of vigorous debate regarding the role of dietary
sugar consumption on health and liver disease, government tax-
ation schemes [20] have arisen as one intervention strategy to
curb the increasing public health concerns over increase SSB con-
sumption. The potential danger of SSB, and in particular fructose,
and its link with various metabolic disorders including NAFLD
has been widely documented and counseling patients, particu-
larly those with pre-existing metabolic syndrome and NAFLD, is
prudent from a public health standpoint. Pending further investi-
gation to support or refute the rising concerns, a call to action for
health care providers to counsel patients at risk of or with diag-
nosed NAFLD on avoidance of SSB as a modiﬁable risk factor for
NAFLD acquisition and progression, is warranted.Conﬂict of interest
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